Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O95150

UPID:
TNF15_HUMAN

ALTERNATIVE NAMES:
TNF ligand-related molecule 1; Vascular endothelial cell growth inhibitor

ALTERNATIVE UPACC:
O95150; Q3SX69; Q5VJK8; Q5VWH1; Q8NFE9

BACKGROUND:
The protein Tumor necrosis factor ligand superfamily member 15, with alternative names TNF ligand-related molecule 1 and Vascular endothelial cell growth inhibitor, is pivotal in immune response regulation. Identified by the unique identifier O95150, it functions as a receptor for TNFRSF25 and TNFRSF6B, facilitating NF-kappa-B activation. Its significant roles include the inhibition of vascular endothelial growth and angiogenesis in vitro, and the promotion of caspase activation and apoptosis.

THERAPEUTIC SIGNIFICANCE:
The exploration of Tumor necrosis factor ligand superfamily member 15's functions offers promising avenues for therapeutic intervention. Given its critical role in regulating angiogenesis and apoptosis, targeting this protein could lead to innovative treatments for cancer and other diseases marked by uncontrolled cellular proliferation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.